

P.O. Box 806
Pelham, N.Y. 10803
Telephone: (914) 712-0093
Fax: (914) 712-0094/5

**Cheryl H. Agris, Ph.D.
Attorney at Law**

FAX RECEIVED

JUN 21 2002

GROUP 1600

Fax

OFFICIAL

To: Examiner J. Roark From: Cheryl Agris
Fax: 1-703-305-3014 Pages: 14
Phone: _____ Date: 6/20/02
Re: 09/559,264 (5694.200) CC: _____

☐ Urgent

☐ For Review

☐ Please Comment

☐ Please Reply

• Comments:

NOTICE OF CONFIDENTIALITY

The information contained in and transmitted with this facsimile is subject to the attorney-client privilege, attorney work product, or is confidential and is intended only for the individual or entity designated above. You are hereby notified that any dissemination, distribution, copying, or use of or reliance upon the information contained in and transmitted with this facsimile by or to anyone other than the recipient designated above by the sender is **unauthorized** and **strictly prohibited**. If you have received this facsimile in error or did not receive all pages, please notify Cheryl H. Agris, Ph.D. Attorney at Law at (914) 712-0093 immediately.

Attorney Docket No.: 5694.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al.

Serial No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: Jessica H. Roark

Confirmation No: 2707

For: Inhibition Of Bradykinin Release

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment/Reply
3. Request for Continued Examination (RCE) Transmittal (in duplicate)

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Jessica H. Roark, Confirmation No: 2707, fax number (703) 305-3014.

Respectfully submitted,

Date: June 20, 2002



Cheryl H. Agris, Reg. No. 34,086
Outside Counsel for Novo Nordisk
of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Attorney Docket No.: 5694.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al.

Serial No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: Jessica H. Roark

Confirmation No: 2707

For: Inhibition Of Bradykinin Release

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Final Office Action mailed December 21, 2001.

It is respectfully requested that the time for response to the Final Office Action dated December 21, 2001 be extended for a period of three (3) months from March 21, 2002 to June 21, 2002. The required fee for the extension is estimated to be \$920.


No additional claims fee is required.

In the event that an extension of time is required, Applicants hereby petition for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

Please charge the required extension fees, estimated to be \$920, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: June 20, 2002



Cheryl H. Agris, Reg. No. 34,086
Outside Counsel for Novo Nordisk
of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

14/B
gnd
6/25/02
PATENT

Attorney Docket No.: 5694.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al.

Application No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: J. Roark

For: Inhibition Of Bradykinin Release

AMENDMENT UNDER 37 C.F.R. 1.116Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action dated December 21, 2001, please consider the following amendments and remarks.

IN THE CLAIMS

Please cancel claims 43-52 without prejudice. Please add new claims 53-60:

SVB
C3
B1

1 53. (new) A method for preventing or treating a disorder resulting from release of bradykinin and alterations in endothelial cell permeability in a mammal, wherein said mammal produces heparin binding protein (HBP) that (i) is proteolytically inactive; (ii) is stored in the azurophil granules of polymorphonuclear leukocytes; (iii) is a chemoattractant for monocytes and/or activates monocytes; (iv) has at least about an 80% identity with the amino acid sequence set forth in SEQ ID NO:1; (v) interacts with kininogen resulting in release of bradykinin and (vi) induces alterations in endothelial cell permeability in said mammal, said method comprising administering to said mammal in need thereof, an amount of an anti-

V